Tag Archives: NASDAQ:TXMD

Noble Financial Reaffirms Their Buy Rating on TherapeuticsMD (TXMD)

In a report issued on July 15, Ahu Demir from Noble Financial maintained a Buy rating on TherapeuticsMD (TXMD – Research Report), with a price target of $10.00. The company’s shares closed last Tuesday at $2.24. According to TipRanks.com, Demir

H.C. Wainwright Keeps Their Buy Rating on TherapeuticsMD (TXMD)

In a report issued on March 27, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on TherapeuticsMD (TXMD – Research Report), with a price target of $6.00. The company’s shares closed last Monday at $1.08, close to its 52-week

TherapeuticsMD (TXMD) Gets a Buy Rating from Noble Financial

In a report released yesterday, Ahu Demir from Noble Financial reiterated a Buy rating on TherapeuticsMD (TXMD – Research Report), with a price target of $13.00. The company’s shares closed last Monday at $2.31, close to its 52-week low of

TherapeuticsMD (TXMD) Receives a Buy from H.C. Wainwright

In a report issued on December 20, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on TherapeuticsMD (TXMD – Research Report), with a price target of $7.00. The company’s shares closed last Monday at $2.28, close to its 52-week

TherapeuticsMD (TXMD) Gets a Buy Rating from H.C. Wainwright

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on TherapeuticsMD (TXMD – Research Report), with a price target of $7.00. The company’s shares closed last Monday at $2.85. According to TipRanks.com, Tsao is a

Noble Financial Sticks to Its Buy Rating for TherapeuticsMD (TXMD)

Noble Financial analyst Ahu Demir maintained a Buy rating on TherapeuticsMD (TXMD – Research Report) yesterday. The company’s shares closed last Monday at $3.78. According to TipRanks.com, Demir is a 3-star analyst with an average return of 5.8% and a